论文部分内容阅读
血清甲胎蛋白(AFP)含量的升高被认为是诊断肝细胞癌的敏感指标,但是在某些继发性肝病和肝细胞再生的非恶性肝病患者中也可见升高。作者根据AFP与刀豆球蛋白A结合特性的差别,用亲和层析法和放射免疫分析法测定了原发性肝癌和继发性肝病患者的血清总AFP含量和与刀豆球蛋白A无反应的AFP含量,计算出后者占总AFP的百分率,这个百分率是区分原发性肝癌和继发性肝病的良好指标。作者研究了21例原发性肝癌和8例继发性肝病患者,如果单独根据血清AFP含量则无法区别出来(继发性肝病患者中有1例血清AFP含量很高),但根据无反应AFP百分率则可很好地区分两组病人。原发性肝癌患者的无反应AFP含量低于20%(1.6～18.8%),而继发性肝病患者的无反应AFP含量高于26%(26.6～91.7%)。因此,作者建议该试验可作为两类肝病患者的区别
Elevated serum alpha-fetoprotein (AFP) levels are considered to be sensitive markers for the diagnosis of hepatocellular carcinoma, but are also seen to be elevated in some secondary liver disease and hepatocellular regeneration in patients with non-malignant liver disease. According to the difference between the binding characteristics of AFP and concanavalin A, the author determined the total serum AFP levels in patients with primary liver cancer and secondary liver diseases by affinity chromatography and radioimmunoassay, Response AFP content, calculate the latter the percentage of total AFP, this percentage is a good indicator to distinguish between primary liver cancer and secondary liver disease. The authors studied 21 patients with primary hepatocellular carcinoma and 8 patients with secondary liver disease that were indistinguishable on the basis of serum AFP alone (1 case of high serum AFP in patients with secondary liver disease) but based on the presence of nonreactive AFP The percentage is good enough to distinguish between two groups of patients. AFP levels were less than 20% (1.6-18.8%) in patients with primary liver cancer and 26% (26.6-91.7%) in patients with secondary liver disease. Therefore, the authors suggest that the trial be used as a distinction between two groups of patients with liver disease